Trials / Active Not Recruiting
Active Not RecruitingNCT03661866
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 15,000 (estimated)
- Sponsor
- Target PharmaSolutions, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Detailed description
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. The duration of follow-up for participants enrolled in the EU is limited to 5-years. Those within in US and Canada may consent to indefinite follow-up.
Conditions
- Atopic Dermatitis
- Alopecia Areata
- Hidradenitis Suppurativa
- Vitiligo
- Psoriasis
- Chronic Spontaneous Urticaria
Timeline
- Start date
- 2018-12-21
- Primary completion
- 2050-12-01
- Completion
- 2050-12-01
- First posted
- 2018-09-07
- Last updated
- 2026-03-20
Locations
62 sites across 4 countries: United States, Canada, Germany, Spain
Source: ClinicalTrials.gov record NCT03661866. Inclusion in this directory is not an endorsement.